Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis

Phase 2 trial (n=65) found AK002 (lirentelimab), an anti–Siglec-8 antibody that depletes eosinophils and inhibits mast cells, reduced gastrointestinal eosinophils (primary endpoint: −86% vs. 9% placebo; p<0.001) and symptoms (treatment response in 63% vs 5% placebo; p<0.001).

Source:

New England Journal of Medicine